The Case for Vaccine Choice
Weekly Wrap: Ted Kuntz on the Real Range of Vaccine Views

SafeMinds Board Member Albert Enayati Testifies at IACC Meeting

SafeMindslogo_colAlbert Enayati, co-founder and board member of SafeMinds, testified in front of the Interagency Autism Coordinating Committee (IACC) at its January 2016 meeting, to support SafeMinds' recommendation of forming a workgroup on co-occurring conditions with autism. He stressed that there "is an urgent need for a workgroup to follow promising treatment leads, shepherd existing treatments through clinical trials and facilitate FDA approvals and/or mainstream acceptance." 

His full testimony follows:

My name is Albert Enayati. My son regressed into autism after receiving seven vaccines in the space of two days.

Today, I would like to expand on the SafeMinds recommendation to establish a workgroup under the IACC to investigate co-occurring conditions. Many of the most disabling or fatal features that are present in a person on the spectrum are co-morbid conditions. These conditions are amendable to treatment. There is an urgent need for a workgroup to follow promising treatment leads, shepherd existing treatments through clinical trials and facilitate FDA approvals and/or mainstream acceptance. This group would require membership from within the committee as well as significant representation from the broader autism advocacy and research communities. An example is Isaac Kohane, MD of Harvard Medical School[i] who was invited to speak to the IACC in the past and who has the knowledge to advise IACC on this topic. Over the history of the IACC, there has been no coordinated effort to develop treatments for people on the spectrum. 

Despite 1.6 billion dollars in spending, parents still have few options that have been proven effective. Risperdal and Abilify are only appropriate for certain symptoms and have significant side effects. We can and must do better. In 2015, researchers at Johns Hopkins University Medical School in collaboration with Massachusetts General Hospital for Children determined that chemicals extracted from broccoli sprouts may help ease autism symptoms[ii] . In another published paper, researchers at Stanford University found that symptoms of autism can be caused by a gene mutation that both blocks the body's natural production of endocannabinoids and also interferes with the way cannabinoids communicate with the brain[iii]. These leads need immediate follow-up and there is currently no mechanism to ensure this. 

There are existing medications such as antibiotics, pioglitazone (Actos), and naltrexone that need further study in autism. In addition, there are vitamins and supplements such as folinic acid, melatonin, methyl B-12, carnitine, folinic acid, probiotics and tetrahydrobipterin that have preliminary evidence of efficacy, but need further study. Lastly, many psychiatric medications are prescribed off-label for those with autism despite lack of properly controlled clinical trials and long-term safety studies in this population. A toll-free number and the IAN surveys should be used to collect community input on treatments to be investigated and to report side effects as a way to include the broad community's input. All of these areas need the concentrated attention of a dedicated workgroup to move the research forward. Perhaps most importantly, this workgroup should play a key role in identifying the biomarkers associated with various comorbidities, assessing what treatments might help, and shepherding these treatments through clinical trials. For example, someone with a co-occurring phenotype of PANDAs and tics will have an underlying immune problem (biomarker) and can be treated with an existing and validated intervention (IVIG) for PANDAS. Or, someone with co-occurring irritability and glutathione imbalance can be helped by N-Acetyl Cysteine treatment. We need to investigate broadly what differentiates the biology of people with autism compared to controls and pursue treatments that make sense. Related to all of this, I must draw attention to the fact that the IACCs database of published research in autism is now ridiculously out of date[iv]. 

Read the full post here.

Comments

Benedetta

Bob Moffit:
OH, in that case -- you are right. Exactly right. I did not think of it that way. It is insane, isn't it, that I still give the IACC a look see, and listen to them for hours at a time. Waste of my time.

yeah, You are right!

HansLitten

The thing I like about your presentation Albert , is you haven't asked the IACC to consider vaccination to be the cause , you have told them it is .


correction :
Your conclusion is insanity and it is a good one, but wrong - it has to do with evil, criminal, white COAT crime.

All doctors need to speak out & tell the truth .

Bob Moffit

Hi Bennedetta .. you wrote:

"Your conclusion is insanity and it is a good one, but wrong - it has to do with evil, criminal, white collar crime".

I am not suggesting the IACC is INSANE .. I am suggesting WE and CONGRESS are .. if WE and CONGRESS expect the IACC to be any different going forward.

Benedetta

Bob Moffit:

Thanks for the summary of what the IACC has been doing for the more than the past four years.

Your conclusion is insanity and it is a good one, but wrong - it has to do with evil, criminal, white collar crime.

Albert Enayati; Thanks for trying and I love your list.

Bob Moffit

Albert Enayati, co-founder and board member of SafeMinds, testified:

"The web tool which is designed to allow analysis of IACC’s research only includes articles through 2010. The 2011-2012 Portfolio Analysis Report has been “Coming Soon” for two years now. In 2016, it is imperative that the coordination and availability of research funds have oversight. A 2013 report by U.S. Government accountability office (GAO)[v] concluded” Eighty-four percent of the autism research projects funded by federal agencies had the potential to be duplicative.” Of the 1,206 autism research projects funded by federal agencies from fiscal years 2008 through 2012, 1,018 projects were potentially duplicative because the projects were categorized to the same objectives in the IACCs strategic plan."

How is it possible .. the IACC .. with such a demonstrably poor track record of analyzing, monitoring and reporting the research they fund .. for four years at least .. as well as .. duplicating 84% of IACC's research an independent source determined was duplicative .. meaning .. scarce funds squandered .. verifying research that proved to be unproductive the first time it was conducted .. remains responsible for playing the .. "key role in identifying the biomarkers associated with various comorbidities, assessing what treatments might help, and shepherding these treatments through clinical trials."

Again .. the definition of insanity is to do the same thing over and over again .. in this instance continuing to support the IACC .. expecting the IACC to SUDDENLY improve their dismal performance as we proceed into the future.

THIS IS INSANITY .. no other name for it.

Lisa

I would only say that, as reasonable as this sounds, it does not address the elephant in the room: Chelation. Many parents have reported benefits with chelation. Others have not used drug chelation but have used NAC or glutathione, which are both powerful mercury chelators, and have seen good results. Chelation, both natural and drug, should also be studied. The only government-sponsored chelation study for autism was canceled back in 2007 (I think it was), without explanation, no doubt due to pressure from the drug companies, which would prefer to not only cover up vaccine damage but also to continue prescribing dopamine-blockers (Abilify, Risperdal), which are known to cause brain tissue death and pituitary tumors in adults -- in addition to a host of other terrible side effects -- and have not been studied at all in children.

 Teresa Conrick

Magnificent and perfectly said. Thank you, Albert!

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name and email address are required. Email address will not be displayed with the comment.)